Brain selective inhibition of acetylcholinesterase: A novel approach to therapy for Alzheimer's disease

Progress in Brain Research

Volumn 98, Issue C, 1993, Pages 431-438

  Enz, Albert ^a   Amstutz, Rene ^a   Boddeke, H ^a   Gmelin, G ^a   Malanowski, J ^a  

^a Preclinical Research   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINESTERASE; CARBAMIC ACID DERIVATIVE; CHOLINESTERASE INHIBITOR; HEPTYLPHYSOSTIGMINE; PHYSOSTIGMINE; RIVASTIGMINE; TACRINE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL TISSUE; BRAIN TISSUE; CHOLINERGIC SYSTEM; CONFERENCE PAPER; ELECTROENCEPHALOGRAM; HIPPOCAMPUS; HUMAN; HUMAN TISSUE; INTRAPERITONEAL DRUG ADMINISTRATION; NONHUMAN; ORAL DRUG ADMINISTRATION; RAT; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0027429837     PISSN: 00796123     EISSN: 18757855     Source Type: Book Series    
DOI: 10.1016/S0079-6123(08)62429-2     Document Type: Article

References (18)

1. Becker, R.E., Giacobini, E., Mechanism of cholinesterase inhibition in senile dementia of the Alzheimer's type: clinical, pharmacological and therapeutic aspects. Drug Dev. Res. 12 (1988), 163–195.
2. Becker, R.E., Moriearty, P., Unni, L., The second generation of cholinesterase inhibitors: clinical and pharmacological effects. Becker, R., Giacobini, E., (eds.) Cholinergic Basis for Alzheimer Therapy, 1991, Birkhäuser, Boston, 263–296.
3. Bevan, P., Effect of muscarinic ligands on the electrical activity recorded from hippocampus: a quantitative approach. Br. J. Pharmacol. 82 (1984), 431–440.
4. Dixon, M., The determination of enzyme inhibitor constants. Biochem. J. 55 (1953), 170–171.
5. Ellman, G.L., Courtney, D., Andres, V., Featherstone, R.M., A new rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol. 7 (1961), 88–95.
6. Enz, A., Amstutz, R., Hofmann, A., Gmelin, G., Kelly, P.H., SDZ ENA 713, an acetylcholinesterase-inhibitor with preference for central activity: animal studies. Nagatsu, T., Fisher, A., Yoshida, M., (eds.) Basic, Clinical and Therapeutic Aspects of Alzheimer's and Parkinson's Diseases, 2, 1990, Plenum Press, New York, 425–428.
7. Enz, A., Boddeke, H., Gray, J., Spiegel, R., Pharmacological and clinical-pharmacological properties of SDZ ENA 713, a centrally selective acetylcholinesterase inhibitor. Ann. N.Y. Acad. Sci. 640 (1991), 272–275.
8. Gray, J.A., Enz, A., Spiegel, R., Muscarinic agonists for senile dementia: past experience and future trends. Trends Pharmacol. Sci., 1989, 85–88 Suppl.
9. Greenfield, S.A., Acetylcholinesterase may have novel functions in the brain. Trends Neurosci. 7 (1984), 365–367.
10. Holsboer-Trachler, E., Hatzinger, M., Stohler, R., Hemmeter, U., Gray, J., Mueller, J., Kocher, R., Spiegel, R., Effect of the novel acetylcholinesterase-inhibitor SDZ ENA 713 on sleep in man. Neuropsychopharmacology 8 (1992), 87–92.
11. Holttum, J.R., Gershon, S., The cholinergic model of dementia, Alzheimer's type: progression from the unitary transmitter concept. Dementia 3 (1992), 174–185.
12. Karczmar, A., Exploitable aspects of cholinergic functions, particularly with respect to the EEG, motor, analgesic and mental functions. Jenden, D., Hanin, I., (eds.) Cholinergic Mechanism and Psychopharmacology, 1978, Plenum Press, New York, 679–708.
13. Massoulie, J., Bon, S., The molecular forms of cholinesterase and acetylcholinesterase in vertebrates. Annu. Rev. Neurosci. 5 (1982), 57–106.
14. Morrison, J.F., Walsh, C.T., The behavior and significance of slow binding enzyme inhibitors. Adv. Enzymol. 61 (1988), 201–299.
15. Palacios, J.M., Bolliger, G., Enz, A., Gmelin, G., Malanowski, J., The pharmacological assessment of RS 86 (2-ethyl-8-methyl-2,8-diazospiro-[4,5]-decan-1,3-dion hydrobromide) a potent, specific muscarinic agonist. Eur. J. Pharmacoi. 125 (1986), 45–62.
16. Perry, E.K., The cholinergic hypotheses-ten years on. Br. Med. Bull., 42, 1986, 1 63–69.
17. Siek, G.C., Katz, L.S., Fishman, E.B., Korosi, T.S., Marquis, J.K., Molecular forms of acetylcholinesterase in subcortical areas of normal and demented (Alzheimer-type) patients. Biol. Psychiatry 27 (1990), 573–580.
18. Weinstock, M., Razin, M., Chorev, M., Tasma, Z., Pharmacological activity of novel anticholinesterase agents of potential use in the treatment of Alzheimer's disease. Fisher, A., Hanin, I., Lachman, P., (eds.) Advances in Behavioral Biology, 29, 1986, Plenum Press, New York, 539–549.